報價延遲最少15分鐘:2025/05/12 04:16 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
301.42 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
25.10/29.21
|
|
企業價值
14.19B
|
| 資產負債 |
|
每股賬面淨值
150.91
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
2.88B
|
|
每股收益
48.87
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/12 04:16 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |